BioWorld. Link to homepage.

Clarivate
  • BioWorld
  • BioWorld Science
  • BioWorld Asia
  • Data Snapshots
    • Biopharma
    • Medical technology
    • Infographics: Dynamic digital data analysis
    • Index insights
    • NME Digest
  • Special reports
    • Infographics: Dynamic digital data analysis
    • Hantavirus
    • Trump administration impacts
    • Med-tech outlook 2026
    • Under threat: mRNA vaccine research
    • BioWorld at 35
    • Biopharma M&A scorecard
    • Bioworld 2025 review
    • BioWorld MedTech 2025 review
    • BioWorld Science 2025 review
    • Women's health
    • China's GLP-1 landscape
    • PFA re-energizes afib market
    • China CAR T
    • Alzheimer's disease
    • Coronavirus
    • More reports can be found here

BioWorld. Link to homepage.

  • Sign In
  • Sign Out
  • My Account
Subscribe
BioWorld - Saturday, May 16, 2026
Breaking News: Tracking hantavirus across the globeBreaking News: Tracking hantavirus across the globeBreaking News: Tracking hantavirus across the globe
Home » Topics » BioWorld Science, Neurology/psychiatric

BioWorld Science, Neurology/psychiatric
BioWorld Science, Neurology/psychiatric RSS Feed RSS

Neurology/psychiatric

Miralogx patents new opioid receptor agonists

Oct. 8, 2024
μ-Opioid receptor agonists have been described in a Miralogx LLC patent as potentially useful for anesthesia and sedation and the treatment of anxiety disorders, asthma, depression and pain.
Read More
Neurology/psychiatric

Aquinnah Pharmaceuticals discovers TDP-43 and tau aggregation inhibitors

Oct. 7, 2024
Aquinnah Pharmaceuticals Inc. has identified new TAR DNA-binding protein 43 (TARDBP; TDP-43) aggregation and microtubule-associated protein tau (PHF-tau; MAPT) aggregation inhibitors reported to be useful for the treatment of amyotrophic lateral sclerosis (ALS) and Alzheimer’s disease.
Read More
Brain and blood cells
Neurology/psychiatric

Hi1a demonstrates neuroprotective activity in EAE mice

Oct. 7, 2024
Khalifa University and The University of Queensland presented preclinical data for a novel acid-sensing ion channel 1 (ASIC1) inhibitor, Hi1a, evaluated in models of multiple sclerosis (MS).
Read More
Brain and encephalography
Neurology/psychiatric

MRS-5474 exerts selective effect in epilepsy tissues

Oct. 7, 2024
The adenosine A1 receptor (A1R) modulates ionic conductance in neuronal membrane and contributes to the anticonvulsant and neuroprotective role of the endogenous neuromodulator adenosine. Because A1Rs are present all throughout the body, the development of A1R modulation as antiseizure strategy may face difficulties such as side effects in the heart or other organs.
Read More
Neurology/psychiatric

COG-201 reduces overall excitability in primary mouse cortical neurons

Oct. 4, 2024
It has been previously demonstrated that intranasal treatment with COG-201, an AAV9-shRNA designed to target the down-regulation of the 5-HT2A receptor, significantly decreased anxiety and improved memory in mice and rats.
Read More
Illustration of tau proteins in Alzheimer's disease
Neurology/psychiatric

RI-AG03 targets main promoters of tau protein aggregation at once

Oct. 4, 2024
The increasing knowledge on how protein tau is organized in live cells has shown that the protein forms nanometer-sized hotspots which are different from tau microtubules. These hotspots, essential for aggregation, include (306)VQIVYK(311) and (275)VQIINK(280) aggregation-promoting hotspots, the first found in all tau isoforms and the latter included mainly in 4R isoforms.
Read More
Illustration of human brain and dna
Neurology/psychiatric

Reverse engineering opens path for precisely targeted gene therapies for ALS and FTD

Oct. 4, 2024
By Nuala Moran
Researchers in the U.K. have succeeded in reverse engineering the defective cryptic splicing that drives amyotrophic lateral sclerosis (ALS) and frontotemporal dementia (FTD) to enable precisely targeted delivery of transgenes and therapeutic protein expression in diseased neurons. The technique is compatible with conventional adeno-associated viral vectors that are approved for gene therapy, and can readily be adapted for different transgenes. ALS, FTD and other neurogenerative diseases are underpinned by loss of function of the RNA-binding protein TDP-43 (transactive response DNA-binding protein 43), that normally functions as a key regulator of splicing, protecting the transcriptome from toxic cryptic exons.
Read More
Neurology/psychiatric

US scientists patent ER-β ligands for endometriosis and multiple sclerosis

Oct. 3, 2024
Scientists at University of California and University of Illinois have disclosed compounds acting as estrogen receptor β (ER-β; ESR2) ligands.
Read More
Adult fly brain 3D reconstruction
Neurology/psychiatric

140,000 cells and 50M synapses make 1 adult fly brain

Oct. 2, 2024
By Mar de Miguel
A collaboration led by the Flywire Consortium and comprising hundreds of scientists has completed a whole map of the adult fruit fly brain after several decades of collaborative work. By using electron microscopy and three-dimensional reconstruction supported by AI tools, the researchers have revealed the neural wiring of the Drosophila melanogaster brain, a connectome of 140,000 neurons with 50 million synaptic connections. In the future, researchers could possibly use this map as an artificial in silico model to study the brain as a simulator through its connections, though a lot of work remains to be done for this.
Read More
Neurology/psychiatric

European scientists unveil new EPHX2/QPCTL inhibitors for Alzheimer’s disease

Oct. 2, 2024
Researchers at QPS Clinical Services GmbH and Universitat de Barcelona have divulged dual bifunctional epoxide hydrolase 2 (EPHX2; sEH) and glutaminyl-peptide cyclotransferase-like protein (QPCTL; IsoQC) inhibitors reported to be useful for the treatment of Alzheimer’s disease.
Read More
Previous 1 2 … 95 96 97 98 99 100 101 102 103 … 2803 2804 Next

Popular Stories

  • Today's news in brief

    BioWorld
    BioWorld briefs for May 15, 2026.
  • Illustration of a glowing circle to represent circRNA

    ASGCT 2026: Circular RNA, the new beast in gene and cell therapy

    BioWorld
    Circular RNA (circRNA) is not a new concept, but it is a novel strategy in the field of gene and cell therapy. While mRNA vaccines have revolutionized medicine,...
  • Test tubes, dropper and capsules

    Advancing the 'best of both' – BMS, Hengrui enter $15.2B deal

    BioWorld
    In a deal potentially worth up to $15.2 billion, Jiangsu Hengrui Pharmaceuticals Co. Ltd. is joining efforts with Bristol Myers Squibb Co. to advance 13 early...
  • News in brief

    BioWorld Asia
    BioWorld Asia briefs for May 12, 2026
  • 3D illustration of adeno-associated viruses

    ASGCT 2026: Uncovering the mechanisms of AAV toxicity

    BioWorld
    Gene therapies rely on vectors to reach the target tissue where they act, such as adeno-associated viruses (AAVs) or lipid nanoparticles (LNPs), among other...
  • BioWorld
    • Today's news
    • Analysis and data insight
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Medical technology
    • Newco news
    • Opinion
    • Regulatory
  • BioWorld Science
    • Today's news
    • Biomarkers
    • Cancer
    • Conferences
    • Endocrine/metabolic
    • Immune
    • Infection
    • Neurology/psychiatric
    • NME Digest
    • Patents
  • BioWorld Asia
    • Today's news
    • Analysis and data insight
    • Australia
    • China
    • Clinical
    • Deals and M&A
    • Financings
    • Newco news
    • Regulatory
    • Science
  • More
    • About
    • Advertise with BioWorld
    • Archives
    • Article reprints and permissions
    • Contact us
    • Cookie policy
    • Copyright notice
    • Data methodology
    • Infographics: Dynamic digital data analysis
    • Index insights
    • Podcasts
    • Privacy policy
    • Share your news with BioWorld
    • Staff
    • Terms of use
    • Topic alerts
Follow Us

Copyright ©2026. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing